YEAR-END REPORT 2008 TRIPEP AB (PUBL)

YEAR-END REPORT 2008 TRIPEP AB (PUBL)

•	Research and development costs amounted to SEK 17.1 (21.3) m
•	The loss after tax was SEK -24.9 (-32.7) m
•	Earnings per share were SEK -2.29 (-5.59)
•	Net sales SEK 3,8 (-) m
•	The company carried out a private placement during the fourth quarter 2008
which raised SEK 5 m, and a rights issue which raised approx. SEK 4.9 m before
transaction costs
•	After an interim analysis of available study data in November the last three
patients are enrolled for high-dose treatment in the ChronVac-C® study
•	Tripep secured a US patent which is strengthening our position regarding
ChronVac-C®
•	Patent application filed for a new antibiotic-free formulation of ChronSeal®
in collaboration with Kringle Pharma, Inc. 
•	Tripep has obtained an approval from the Norwegian Medical Products Agency to
start the phase II study with ChronSeal® and the study started in January 2009
•	Tripep secures financing in ChronSeal® through a new agreement with Kringle
Pharma, Inc.

Events after the end of the reporting period
•	Tripep has obtained an approval from the Swedish Medical Products Agency to
start the phase II study with ChronSeal® and the study expects to start in
Sweden in February 2009
•	Through Tripep's partner Kringle Pharma a letter of intent has been signed
with the Japanese specialty pharma company Maruho regarding ChronSeal®


For more information, please contact:
Jan Nilsson, CEO, Tripep AB 		
Tel: +46 8 449 84 80, Mobile phone: +46 70 466 31 63 	
E-mail: jan.nilsson@tripep.se 	

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


About Tripep
Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal® and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB. For more information, please refer to the
company's website: www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.